Actinium Pharmaceuticals (ATNM)
:ATNM
Top Page
Actinium Pharmaceuticals
(ATNM)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-9.91% Downside)
Action:ReiteratedDate:12/30/25
The score is primarily weighed down by weak financial performance—very low revenue, large ongoing losses, and sustained cash burn—partly offset by low leverage. Technicals are neutral-to-weak with the stock trading below key moving averages and only modest momentum. Valuation offers limited support given negative earnings and no dividend.
Positive Factors
Innovative Product Pipeline
The ARC platform represents a significant competitive advantage, potentially offering targeted cancer therapies that spare healthy tissue, which could lead to successful commercialization and partnerships.
Negative Factors
Negative Revenue Growth
Consistent revenue decline indicates challenges in product commercialization and market penetration, potentially limiting future growth and financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Pipeline
The ARC platform represents a significant competitive advantage, potentially offering targeted cancer therapies that spare healthy tissue, which could lead to successful commercialization and partnerships.
Read all positive factors
Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.69M
Dividend YieldN/A
Average Volume (3M)208.30K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue Growth11.11%
EPS Growth20.65%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding31,195,890
10 Day Avg. Volume380,172
30 Day Avg. Volume208,296
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-1.15
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-216.58
Enterprise Value/Gross Profit26.74
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.8
Revenue Forecast (FY)N/A
Actinium Pharmaceuticals Business Overview & Revenue Model
Company Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product...
How the Company Makes Money
Actinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceuti...
Actinium Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.00K | 0.00 | 81.00K | 1.03M | 1.14M | 0.00 |
| Gross Profit | -729.00K | -811.00K | 81.00K | 1.03M | 620.00K | -447.00K |
| EBITDA | -33.78M | -37.43M | -51.13M | -33.41M | -24.25M | -21.77M |
| Net Income | -34.60M | -38.24M | -48.82M | -33.02M | -24.77M | -22.21M |
Balance Sheet | ||||||
| Total Assets | 56.15M | 76.90M | 81.44M | 114.19M | 80.39M | 66.40M |
| Cash, Cash Equivalents and Short-Term Investments | 53.39M | 72.90M | 76.68M | 108.91M | 77.83M | 63.61M |
| Total Debt | 1.14M | 1.57M | 2.11M | 2.58M | 310.00K | 738.00K |
| Total Liabilities | 42.37M | 44.14M | 45.07M | 47.71M | 6.84M | 5.08M |
| Stockholders Equity | 13.78M | 32.76M | 36.38M | 66.48M | 73.55M | 61.32M |
Cash Flow | ||||||
| Free Cash Flow | -25.04M | -33.08M | -47.49M | 8.28M | -21.00M | -21.87M |
| Operating Cash Flow | -25.04M | -33.07M | -47.34M | 8.64M | -20.87M | -21.62M |
| Investing Cash Flow | 0.00 | -11.00K | -153.00K | -366.00K | -133.00K | -253.00K |
| Financing Cash Flow | -217.00K | 29.32M | 14.87M | 23.11M | 35.22M | 76.18M |
Actinium Pharmaceuticals Technical Analysis
Negative
1.11
Price Trends
1.17
Negative
1.30
Negative
1.45
Negative
Market Momentum
-0.02
Positive
42.44
Neutral
23.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.11 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.17, and below the 200-day MA of 1.45, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.44 is Neutral, neither overbought nor oversold. The STOCH value of 23.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.
Actinium Pharmaceuticals Risk Analysis
Actinium Pharmaceuticals disclosed 59 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Actinium Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $67.98M | -1.32 | -81.77% | ― | ― | ― | |
46 Neutral | $75.39M | -2.93 | -341.33% | ― | ― | 42.29% | |
45 Neutral | $33.69M | -2.43 | -151.67% | ― | 11.11% | 20.65% | |
44 Neutral | $142.92M | -3.28 | -184.07% | ― | ― | 66.05% |
* Healthcare Sector Average
ATNM
Actinium Pharmaceuticals
1.08
-0.81
-42.86%
IFRX
InflaRx
0.94
-0.31
-24.80%
GANX
Gain Therapeutics
1.96
-0.11
-5.31%
UNCY
Unicycive Therapeutics
6.65
0.39
6.23%
ANL
Adlai Nortye Ltd. Sponsored ADR
7.12
4.94
226.61%
JUNS
Jupiter Neurosciences, Inc.
0.35
-0.39
-52.70%
Actinium Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Actinium Pharmaceuticals Holds Annual Stockholders Meeting
Neutral
Nov 26, 2025
On November 26, 2025, Actinium Pharmaceuticals held its annual meeting of stockholders, where Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors for a term expiring in 2028. The meeting also saw the ratification of CBIZ as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.